RBC Capital analyst Leonid Timashev raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $302.00 (from $242.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Axsome Therapeutics (AXSM) PT Raised to $280 at OppenheimerMay 4, 2026 3:19 PM Axsome Therapeutics (AXSM) PT Raised to $260 at GuggenheimMay 4, 2026 1:15 PM Axsome Therapeutics (AXSM) PT Raised to $258 at Piper SandlerMay 4, 2026 12:23 PM Axsome Therapeutics (AXSM) PT Raised to $275 at TD CowenMay 4, 2026 12:06 PM Axsome Therapeutics (AXSM) PT Raised to $270 at H.C. WainwrightMay 4, 2026 7:28 AM Form 8-K Axsome Therapeutics, For: May 04May 4, 2026 7:08 AM Axsome Therapeutics (AXSM) Misses Q1 EPS by 43cMay 4, 2026 7:01 AM Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 4, 2026 7:00 AM Axsome Therapeutics (AXSM) PT Raised to $255 at TD CowenMay 1, 2026 11:25 AM Axsome Therapeutics (AXSM) PT Raised to $241 at BairdMay 1, 2026 8:20 AM Axsome AUVELITY wins FDA approval for Alzheimer's agitation treatmentMay 1, 2026 7:15 AM Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought LeaderMay 1, 2026 7:15 AM Form 8-K Axsome Therapeutics, For: Apr 30April 30, 2026 5:19 PM Axsome Therapeutics (AXSM) PT Raised to $250 at OppenheimerApril 30, 2026 5:15 PM Axsome Therapeutics (AXSM) PT Raised to $217 at Morgan StanleyApril 30, 2026 3:23 PM Axsome receives FDA approval for AUVELITY to treat Alzheimer's agitationApril 30, 2026 2:06 PM Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s DiseaseApril 30, 2026 2:06 PM Axsome Therapeutics (AXSM) Halted, News PendingApril 30, 2026 2:05 PM